$TSOI HUGE COVID19 drug NEWS NEWS Therapeutic Solutions

New Post Public Reply Private Reply Replies (0) Message Board
stock-scamper
810
$TSOI HUGE COVID19 drug NEWS NEWS
Therapeutic Solutions International Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune™
San Diego Top Doctor James Veltmeyer Leads Efforts to Demonstrate Efficacy of Immune Boosting Formulation in High-Risk Population
OCEANSIDE, California, June 8, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting formulation QuadraMune™.

The trial is anticipated to recruit 500 subjects at risk of SARS-CoV-2 infection, the type of coronavirus which causes COVID-19.

The new clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 and is expected to appear on the Federal Clinical Trial registry this week.

Last week the Company announced data from a preliminary clinical trial in which four groups of eight volunteers were treated with placebo or escalating doses of QuadraMune™[1]. Elevation of innate immune response activity was observed, together with a decreased responsiveness towards inflammatory stimuli. These preliminary data were analyzed by the Company's Scientific Advisory Board, who then recommended proceeding to the larger trial.

"At Therapeutic Solutions International we believe only in hard science. As a medical doctor who is on the frontlines of the war with Coronavirus, I and my staff take QuadraMune™ daily," said James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and "Top Doctor" of San Diego in 2012, 2014, 2016, 2017, and 2019. "The laboratory and early clinical results seen with QuadraMune™ are truly inspiring. We believe the time has come to jump into a large clinical trial to generate the data necessary to truly convince our colleagues and the world of the potential efficacy of this immune-stimulatory and anti-inflammatory approach."

The clinical trial calls for the daily administration of QuadraMune™ for a period of twelve weeks. Rates of infection will be assessed compared to controls. Subjects eligible to enter the trial are high-risk individuals, which are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities.

"If you look historically at pandemics, almost all of them have a Second Wave, which is almost always substantially more devastating than the first. We at Therapeutic Solutions International are pleased to apply our work in the area of inflammation and immune stimulation, to attempt to add another arrow in our quiver against this invisible enemy," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In some ways, Coronavirus is like cancer…you want to increase activation of innate immunity and suppress inflammatory reactions simultaneously. We have been doing this research successfully using NanoStilbene™ in cancer, and now we are transposing our findings into the field of virology."

A pre-publication copy, of the submitted manuscript of the preliminary clinical trial, is available by following this link: https://therapeuticsolutionsint.com/CV/JTRM-D-20-01014.pdf.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on QuadraMune™ visit www.areyoucovidmune.com/covidmune/.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

1. https://www.biospace.com/article/releases/the...-covid-19/

Company Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune™
Contact:
Timothy Dixon
+1-(760)-295-7208
Therapeutic Solutions International, Inc.
ir@tsoimail.com

https://c212.net/c/img/favicon.png?sn=LN28035...2020-06-08 View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-initiates-500-volunteer-covid-19-prevention-clinical-trial-using-quadramune-301071981.html

SOURCE Therapeutics Solutions International, Inc.

Progressive Insurance
Sponsored By: Progressive Insurance
Save extra just by protecting your home and car together! Get a FREE Quote

Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings

Pink Current Information

DAILY ADVANCERS
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Enter your email
SIGN UP
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovative Trial Targets Drug Resistance in Lung Cancer

Updated Category News Views 53

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Continue Reading
Eric Dalton: Redefining Homecare with Vision and Strategy

Updated Category News Views 59

What's Behind Eric Dalton's Continued Recognition? Now, if you told me a healthcare leader’s named 'Visionary of the Year' twice in a row, my first thought isn't 'stretch goals' but 'show me the goods.' And that’s precisely what Eric J. Dalton has done. The Vice President at Angels on Call Homecare isn't just tooting his own horn; he's building a damn symphony in the...

Continue Reading
Software Updates Costly: UX Not the Biggest Culprit

Updated Category News Views 109

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 37

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
AppGate Rises as 2026 Leader in Digital Risk

Updated Category News Views 67

AppGate: Forging a Path in Digital Security In a world where cyber threats seem to lurk around every digital corner, snagging the title of a leader in digital risk protection from the SPARK Matrix is no small feat. Let’s dive deep into AppGate’s rise to the top in QKS Group’s 2026 evaluation. What Sets AppGate Apart? AppGate's leadership status isn't some overnight...

Continue Reading
McKinsey and Parloa Join Forces on AI Customer Service

Updated Category News Views 60

AI-Revolutionizing Customer Service: The New Partnership Out of the boardroom and into the trenches, McKinsey joins hands with Parloa, aiming to reshape how enterprises handle customer service through artificial intelligence. Forget all the corporate fluff you've heard before; these guys are dead set on closing the massive gap companies face in deploying AI agents...

Continue Reading
Fannie Mae Q3 2026 Earnings Surpass Expectations

Updated Category News Views 35

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Continue Reading
BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 65

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
BetaNXT and Pave Finance Transform Wealth Management

Updated Category News Views 52

AI Takes Center Stage in Wealth Management You know, it's not every day we see two powerhouses like BetaNXT and Pave Finance buddying up to shake up the financial advisory world. This partnership's all about harnessing AI to give wealth management firms and financial advisors some serious firepower in portfolio planning. BetaNXT, already a big name with its slick...

Continue Reading
Getlabs Brings GI Test Kits to Your Doorstep

Updated Category News Views 106

Home Testing: A Game Changer for GI Patients Imagine dragging yourself out of bed, managing gut issues, only to face a grueling trip to a lab. It's the last thing a patient with GI symptoms wants. Enter Getlabs and Genova Diagnostics with a welcome shift: a partnership that promises to bring the lab to your doorstep—literally. The Partnership Expansion Getlabs, the...

Continue Reading

Top 5 Most Recently Viewed Articles

Infortar's Share Buyback Strategy and Recent Transactions

Updated Category News Views 176

Infortar's Share Buyback Strategy Infortar is actively engaging in a share buyback program on the Nasdaq Tallinn Stock Exchange. This initiative reflects a strategic approach towards securing and stabilizing their market presence. During a recent period, Infortar made notable acquisitions of its own shares, an activity that signals confidence in its long-term value....

Continue Reading
Cisco's Stock Surges to New Heights Amid Innovative Growth

Updated Category News Views 349

Cisco Sets New Milestone with 52-Week High Cisco Systems Inc (NASDAQ: CSCO) has achieved a remarkable milestone as its shares soared to a 52-week high of $60.23. This surge reflects the company's impressive growth trajectory and consistent performance over the past year. With a current market capitalization of $239.6 billion, analysts suggest that the stock may be...

Continue Reading
Insight into Life Science REIT Plc's Recent Disclosure Process

Updated Category News Views 124

Understanding the Disclosure Process for Life Science REIT Plc The disclosure of relevant securities for companies listed on the stock exchange is crucial for maintaining transparency and regulatory compliance. One important example is the recent public opening position disclosure by Life Science REIT Plc, a notable name in the real estate investment trust sector. This...

Continue Reading
November Energy Stocks Worth Watching: High Potential Picks

Updated Category News Views 874

Opportunities in Oversold Energy Stocks In the energy sector, there is often potential for long-term gains hidden within oversold stocks. When a stock exhibits an oversold condition, it's usually an indicator that investor sentiment has driven the price down more than justified by the company's fundamentals. This presents a buy opportunity for savvy investors....

Continue Reading
Terranet's Technology Development Progress Report

Updated Category News Views 104

Terranet's Technology Development Progress Report Recently, Terranet has shared updates with stakeholders regarding its advancements in technology during the second quarter. The company has begun the initial integration of its system into a vehicle, which will lead to an expanded testing phase that will be reported back to the market. The analyses confirm that the ongoing...

Continue Reading